SignaBlok wins NHLBI / NIH SBIR Phase II grant to test SignaBlok’s ultra high sensitivity MRI contrast agents for atherosclerosis imaging in rodent and non-rodent animal models

SignaBlok > News > SignaBlok wins NHLBI / NIH SBIR Phase II grant to test SignaBlok’s ultra high sensitivity MRI contrast agents for atherosclerosis imaging in rodent and non-rodent animal models

SignaBlok wins NHLBI / NIH SBIR Phase II grant to test SignaBlok’s ultra high sensitivity MRI contrast agents for atherosclerosis imaging in rodent and non-rodent animal models

Vera

View posts by Vera
Scroll to top